S-1/A: SRx Health Solutions Shifts to Pet Wellness, Secures $1B ELOC

SRx Health Solutions, Inc. is undergoing a significant transformation, divesting its Canadian healthcare operations to focus on its Halo pet health and wellness business, while securing substantial financing through an Equity Line of Credit.

Summary

• SRx Health Solutions, Inc. (formerly Better Choice Company Inc.) completed a reverse merger with SRx Canada on April 24, 2025, with Better Choice changing its name to SRx Health Solutions, Inc. and SRx Canada becoming the accounting acquirer.
• SRx Canada's legacy specialty pharmaceuticals and healthcare services operations were classified as discontinued operations and filed for protection under the Companies Creditors Arrangement Act (CCAA) in Canada on August 12, 2025.
• The company's continuing operations are now solely focused on the Halo pet health and wellness business, offering premium and super-premium pet food and wellness products.
• Halo strategically exited Petco stores (remaining on Petco.com) and Pet Supplies Plus in December 2023, and its Direct-to-Consumer (DTC) channel on June 1, 2024, to improve profitability, directing consumers to Amazon and Chewy.
• The company sold its Asian business in April 2025 for total gross proceeds of $8.1 million, including $6.5 million in cash and a 5-year royalty agreement.
• A July PIPE Financing on July 7, 2025, involved the issuance of $7.65 million in senior secured convertible notes (8% interest, maturing July 8, 2027) and warrants for 21,338,062 common shares at an exercise price of $0.6274.
• An October PIPE Financing on October 27, 2025, allowed for the purchase of up to 38,070 Series A convertible preferred stock and warrants for up to $30.46 million. A first closing on October 31, 2025, raised approximately $15.23 million, partly through cash and partly by canceling July Notes and Warrants.
• The company entered into an Equity Line of Credit (ELOC) with Keystone Capital Partners, LLC, on July 7, 2025, which was amended on October 28, 2025, to increase the total commitment from $50 million to $1.0 billion.
• In connection with the ELOC amendment, a $20.0 million convertible promissory note was issued to Keystone, convertible into up to 50,137,880 shares of Common Stock at an assumed price of $0.3989 per share.
• The ELOC allows the company to sell up to 2,506,893,959 shares of Common Stock to Keystone at a discount to the market price, which represents approximately 91.9% of the total fully diluted outstanding shares as of the date of the prospectus.
• For the year ended September 30, 2025, continuing operations (Halo) reported net sales of $6,534 thousand, a gross profit of $1,526 thousand (23% gross margin), and a net loss from continuing operations of $(8,639) thousand.
• Adjusted EBITDA from continuing operations for the year ended September 30, 2025, was $(1,762) thousand.
• The company's cash and cash equivalents were $1,309 thousand as of September 30, 2025.
• The company received a notice from NYSE American on October 14, 2025, regarding non-compliance with continued listing standards due to stockholders' equity below $4 million while reporting losses.
• The number of authorized common shares was increased from 200,000,000 to 5,000,000,000 on November 19, 2025.

Sentiment

Score: 3

Explanation: The company is undergoing a critical restructuring, divesting a failed segment to focus on a smaller, but potentially more viable, pet wellness business. While significant capital has been secured, the 'going concern' doubt, ongoing losses, and substantial potential dilution from the ELOC present high risks. The NYSE delisting notice further underscores the precarious financial position. The sentiment is negative due to the severe challenges, despite the strategic pivot and capital infusion.

Positives

• The company is strategically exiting unprofitable legacy healthcare operations (SRx Canada) to focus on the more promising Halo pet health and wellness business.
• Halo's pet health and wellness segment generated $6.5 million in net sales for the year ended September 30, 2025, with a 23% gross margin, indicating a viable core business.
• Securing a substantial $1.0 billion Equity Line of Credit (ELOC) from Keystone Capital Partners provides significant potential capital for working capital and general corporate purposes, offering financial flexibility.
• The company has successfully raised $8.8 million in a private placement and $15.23 million in an October PIPE Financing, demonstrating access to capital markets.
• Management believes the streamlined business model provides a clearer path to operational stability and disciplined execution.
• The company's focus on digital channels (Amazon, Chewy) and brand awareness is expected to drive future growth and improve media effectiveness and efficiency.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital and historical net losses.
• The company reported a net loss from continuing operations of $(8,639) thousand and a total net loss of $(45,006) thousand for the year ended September 30, 2025.
• Adjusted EBITDA from continuing operations was negative at $(1,762) thousand for the year ended September 30, 2025.
• The company is not in compliance with NYSE American continued listing standards, facing potential delisting if it cannot cure the deficiency by July 14, 2026.
• The sale of up to 2,506,893,959 shares by the Selling Stockholder (Keystone Capital Partners), representing approximately 91.9% of total fully diluted outstanding shares, could cause significant dilution and depress the stock price.
• The purchase price for shares sold to Keystone under the ELOC will be at a discount to the market price, potentially leading to further dilution for existing shareholders.
• The company relies heavily on a limited number of suppliers (85% from three vendors) and customers (98% of receivables and 88% of gross sales from three customers), posing concentration risks.
• The Canadian specialty healthcare business (SRx Canada) filed for CCAA protection and its assets are being sold, indicating a failure of previous strategic direction and significant losses from discontinued operations.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, making it difficult to secure additional financing.
• Incurring significant losses in prior periods and potential future losses could cause the stock price to decline and adversely affect financial condition.
• Inability to successfully implement growth strategy or effectively manage anticipated growth could harm the business.
• Loss of key members of senior management team could impair the ability to execute the business plan.
• Inability to generate sufficient cash flow or raise capital on acceptable terms to run operations, service debt, and make necessary capital expenditures.
• Dependence on subsidiaries for payments, advances, and transfers of funds due to holding company status.
• Inability to successfully develop additional products and services or successfully commercialize them.
• Intense competition in the pet health and wellness market from companies with greater resources.
• Vulnerability to fluctuations in the price and supply of key inputs, including ingredients, packaging materials, and freight.
• Food safety and food-borne illness incidents could lead to lawsuits, product recalls, regulatory actions, and reduced demand.
• Reliance on third-party commerce platforms (e.g., Amazon, Chewy) exposes the company to risks if platforms are compromised or relationships deteriorate.
• International expansion exposes the company to substantial business, regulatory, political, financial, and economic risks.
• Decreased spending on pets in a challenging economic climate could reduce demand for premium products.
• Significant merchandise returns or refunds could harm the business.
• Failure to successfully integrate future acquisitions or strategic alliances could materially adversely affect anticipated benefits.
• Premiums for insurance coverage may not continue to be commercially justifiable, or coverage may be insufficient.
• Claims of intellectual property infringement by third parties could be expensive and disruptive.
• Failure to comply with anti-corruption and anti-bribery laws (e.g., FCPA) and trade control laws could lead to penalties.
• Ability to utilize net operating loss carryforwards may be limited by Section 382 of the Code due to ownership changes.
• Non-compliance with extensive governmental regulations (FDA, FTC, USDA) for animal food products could lead to enforcement actions or recalls.
• Changes in government regulations and trade policies, particularly between the U.S. and China, could adversely affect sales and operations.
• The company's common stock may be deemed a 'penny stock,' making it more difficult for investors to trade.
• Failure to meet NYSE American continued listing requirements could result in delisting, making it harder to raise capital.
• The market price of common stock may be highly volatile due to various factors, including sales by affiliates.
• Future sales of common stock, especially under the ELOC, will likely cause substantial dilution to existing shareholders and could depress the share price.
• Management has broad discretion over the use of ELOC proceeds, which may not necessarily improve financial condition or market value.

Future Outlook

The company's outlook reflects the early stages of a significant reset, with near-term priorities focused on strengthening the financial position of the continuing Halo pet health and wellness operations, optimizing cost structure, and re-establishing a focused growth path. Management will continue evaluating strategic alternatives, including potential partnerships, product expansion, and targeted investments. The company does not expect to have positive cash flow until the end of 2025 or longer.

Management Comments

• Management believes that the streamlined business provides a clearer path to operational stability and disciplined execution.
• Management believes it is in the company's best interests to have the flexibility to sell Common Shares pursuant to the ELOC Purchase Agreement, subject to market conditions.
• Management believes Halo is better equipped to customize products for the pet health and wellness market generally as compared to other companies in the industry.

Industry Context

The company is shifting its focus entirely to the pet health and wellness industry, a sector benefiting from mainstream trends of growing pet humanization and consumer focus on health and wellness. This move positions the company to capitalize on a market that values premium and super-premium products. However, the industry is highly competitive, with established players and new entrants, requiring strong brand differentiation, effective marketing, and continuous innovation. The company's reliance on e-commerce platforms like Amazon and Chewy aligns with increasing digital consumer purchasing behaviors in the pet sector.

Comparison to Industry Standards

• The company's gross margin of 23% for its continuing Halo operations for the year ended September 30, 2025, should be assessed against industry averages for premium pet food companies. While the filing does not provide specific comparable company data, typical gross margins in the specialty pet food sector can range from 25% to 45% depending on product type, distribution channels, and brand positioning. A 23% margin suggests room for improvement or indicates a highly competitive pricing environment.
• The company's significant customer and supplier concentration (98% of receivables and 88% of gross sales from three customers; 85% of inventory from three vendors) is higher than industry best practices for risk diversification. Leading companies like Mars Petcare or Nestlé Purina, for example, typically have a much broader customer and supplier base to mitigate reliance on a few key relationships.
• The company's negative Adjusted EBITDA of $(1.762) million for continuing operations indicates that the core pet wellness business is not yet profitable, which is below the performance of established, profitable industry players such as Blue Buffalo (General Mills) or Merrick (Nestlé), which consistently report positive EBITDA and strong profitability metrics. This suggests the company is in a turnaround or growth investment phase.
• The company's NYSE American delisting notice due to low stockholders' equity and recurring losses is a significant concern, contrasting sharply with the financial stability and robust equity positions of major publicly traded pet food companies.

Management Changes

Corporate Governance

Legal Proceedings

• SRx Canada, a wholly-owned subsidiary, initiated restructuring proceedings under the federal Companies Creditors Arrangement Act (CCAA) in Canada on August 12, 2025.
• The Ontario Superior Court of Justice (Commercial List) granted a stay of proceedings for SRx Canada, appointed a monitor, granted debtor-in-possession financing, and approved sale procedures for SRx Canada's assets.
• Court approved transactions for the sale of substantially all of SRx Canada's assets and businesses on August 21, 2025, and October 29, 2025, with the majority completed.
• The stay of proceedings for SRx Canada has been extended to January 30, 2026, to complete the restructuring.
• Neither SRx Health Solutions, Inc. nor its U.S. subsidiary, Halo, Purely For Pets, Inc., has made any bankruptcy filing.

Related Party Transactions

• As of September 30, 2025, certain members of the Board of Directors held outstanding convertible promissory notes totaling $0.5 million, bearing 8% interest and convertible into common stock.
• For the fiscal year ended September 30, 2025, continuing operations incurred approximately $0.7 million in director fees, of which $0.5 million were settled in exchange for convertible notes.
• During the year ended September 30, 2025, the company issued an aggregate of $3.2 million in share-based compensation to its directors and executive officers.
• During the year ended September 30, 2025, the company paid its executive officers an aggregate of $1.0 million in compensation.
• In January 2025, a revolving credit facility (Promissory Note) with Better Choice Company Inc. (BTTR) was amended to convert the outstanding balance into common shares of the company upon the closing of the business combination between the company and BTTR. This note was personally guaranteed by Adesh Vora, former CEO.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the ELOC agreement (up to 91.9% of fully diluted shares) and other equity issuances, which could depress the stock price. The 'going concern' doubt and NYSE delisting risk pose substantial threats to investment value. However, the ELOC provides a potential source of capital to fund operations and growth, which could be beneficial if the company successfully executes its new strategy.
• **Employees**: The company has a small team (10 full-time, 1 part-time) focused on the Halo business. The shift to a 'Win From Anywhere' culture aims to attract and retain talent. The discontinuation of SRx Canada operations likely resulted in job losses in that segment, but the remaining employees are critical to the new strategic focus.
• **Customers (Halo)**: The strategic exits from Petco stores (physical) and the DTC channel, redirecting to Amazon and Chewy, aim to improve profitability and reach. This could streamline the customer experience for online shoppers but may impact those who preferred direct purchases or specific physical retail locations.
• **Suppliers (Halo)**: The company's high reliance on three main vendors (85% of purchases) creates concentration risk for its supply chain. Any disruption or change in terms with these suppliers could significantly impact product availability and costs.
• **Creditors**: The CCAA proceedings for SRx Canada indicate that creditors of that segment are subject to a court-supervised restructuring process, with the CWB debt deconsolidated from the company's financial statements. The July PIPE notes were settled post-September 30, 2025, through the October PIPE, indicating a restructuring of debt obligations.

Next Steps

• The company needs to submit a plan to NYSE American by November 13, 2025, to regain compliance with listing standards.
• The company must cure the NYSE American listing deficiency by July 14, 2026, to avoid delisting.
• Completion of the restructuring of SRx Canada under CCAA proceedings is expected by January 30, 2026.
• The company plans to file a registration statement with the SEC to register for resale the Common Stock issuable upon conversion of the Series A Preferred Stock and exercise of the October Warrants.
• Management will continue to evaluate strategic alternatives to support the long-term viability of the business, including potential partnerships, product expansion opportunities, and targeted investments.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by the 'going concern' doubt from its independent auditors and a notice of non-compliance with NYSE American listing standards, which could lead to delisting. While the strategic pivot to the Halo pet wellness business and the securing of a $1.0 billion Equity Line of Credit (ELOC) are attempts to stabilize, the core business is currently unprofitable (negative Adjusted EBITDA) and the ELOC carries a massive potential for dilution (up to 91.9% of fully diluted shares). The sale of shares by Keystone at a discount to market price will exert significant downward pressure on the stock. The historical losses, ongoing cash burn from operations, and the failure of the previous healthcare segment (SRx Canada's CCAA filing) paint a picture of extreme risk and uncertainty. A seasoned investor would view the substantial dilution, precarious financial position, and high operational risks as overwhelmingly negative, making the stock a strong sell.

Keywords

Pet Health, Pet Wellness, Halo, SEC Filing, S-1/A, Equity Line of Credit, ELOC, Keystone Capital Partners, Dilution, Going Concern, NYSE American, Delisting Risk, Convertible Notes, Warrants, Private Placement, CCAA, Restructuring, Specialty Pharmacy, Animal Food, E-commerce, Supply Chain Risk, Corporate Governance